The phosphate regulating hormone fibroblast growth factor-23

Acta Physiologica

Volumn 200, Issue 2, 2010, Pages 97-106

  Marsell, R ^a   Jonsson, K B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

fibroblast growth factor 23; osteomalacia; parathyroid hormone; phosphate; rickets

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE;

BIOCHEMISTRY; CARDIOVASCULAR DISEASE; GENETIC DISORDER; HOMEOSTASIS; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; PHOSPHATES; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 77956333482     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/j.1748-1716.2010.02163.x     Document Type: Review

References (98)

1. ADHR-consortium. 2000. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26, 345 348.
2. Aono, Y., Yamazaki, Y., Yasutake, J., Kawata, T., Hasegawa, H., Urakawa, I., Fujita, T., Wada, M., Yamashita, T., Fukumoto, S. Shimada, T. 2009. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 24, 1879 1888.
3. Arnaud, C., Glorieux, F. Scriver, C. 1971. Serum parathyroid hormone in X-linked hypophosphatemia. Science 173, 845 847.
4. Asnes, R.S., Berdon, W.E. Bassett, C.A. 1981. Hypophosphatemic rickets in an adolescent cured by excision of a nonossifying fibroma. Clin Pediatr (Phila) 20, 646 648.
5. Aubin, J.E. Bonnelye, E. 2000. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 11, 905 913.
6. Bai, X.Y., Miao, D., Goltzman, D. Karaplis, A.C. 2003. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278, 9843 9849.
7. Beck, L., Karaplis, A.C., Amizuka, N., Hewson, A.S., Ozawa, H. Tenenhouse, H.S. 1998. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci U S A 95, 5372 5377.
8. Ben-Dov, I.Z., Galitzer, H., Lavi-Moshayoff, V., Goetz, R., Kuro-o, M., Mohammadi, M., Sirkis, R., Naveh-Many, T. Silver, J. 2007. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117, 4003 4008.
9. Benet-Pages, A., Lorenz-Depiereux, B., Zischka, H., White, K.E., Econs, M.J. Strom, T.M. 2004. FGF23 is processed by proprotein convertases but not by PHEX. Bone 35, 455 462.
10. Benet-Pages, A., Orlik, P., Strom, T.M. Lorenz-Depiereux, B. 2005. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14, 385 390.
11. Bilezikian, J. 2002. Actions of parathytoid hormone. In : J. Bilezikian, L. Raisz T. Martin (eds) Principles in Bone Biology, pp. 463 481. Academic Press, San Diego.
12. Block, G.A., Klassen, P.S., Lazarus, J.M., Ofsthun, N., Lowrie, E.G. Chertow, G.M. 2004. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15, 2208 2218.
13. Bowe, A.E., Finnegan, R., Jan de Beur, S.M., Cho, J., Levine, M.A., Kumar, R. Schiavi, S.C. 2001. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284, 977 981.
14. Brown, W.W., Juppner, H., Langman, C.B., Price, H., Farrow, E.G., White, K.E. McCormick, K.L. 2009. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab 94, 17 20.
15. Burnett, S.M., Gunawardene, S.C., Bringhurst, F.R., Juppner, H., Lee, H. Finkelstein, J.S. 2006. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21, 1187 1196.
16. Cannata-Andia, J.B. Rodriguez-Garcia, M. 2002. Hyperphosphataemia as a cardiovascular risk factor - how to manage the problem. Nephrol Dial Transplant 17 (Suppl. 11 16 19.
17. Chefetz, I. Sprecher, E. 2009. Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis. Biochim Biophys Acta 1792, 847 852.
18. Cheng, L. Sacktor, B. 1981. Sodium gradient-dependent phosphate transport in renal brush border membrane vesicles. J Biol Chem 256, 1556 1564.
19. DeLuca, H.F. 2004. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80, 1689S 1696S.
20. Drezner, M.K. 2002. Phosphourous homeostasis and related disorders. In : J. Bilezikian, L. Raisz T. Martin (eds) Principles of Bone Biology, pp. 321 338. Academic Press, San Diego.
21. Econs, M. White, K.E. 1997. Inherited phosphate wasting disorders. In : M. Econs (ed) The Genetics of Osteoporosis and Metabolic Bone Disease, pp. 47 52. Humana Press Inc, New Jersey.
22. Farrow, E.G., Davis, S.I., Summers, L.J. White, K.E. 2009. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20, 955 960.
23. Feng, J.Q., Ward, L.M., Liu, S., Lu, Y., Xie, Y., Yuan, B., Yu, X., Rauch, F., Davis, S.I., Zhang, S., Rios, H., Drezner, M.K., Quarles, L.D., Bonewald, L.F. White, K.E. 2006. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38, 1310 1315.
24. Fukumoto, S. Martin, T.J. 2009. Bone as an endocrine organ. Trends Endocrinol Metab 20, 230 236.
25. Garringer, H.J., Fisher, C., Larsson, T.E., Davis, S.I., Koller, D.L., Cullen, M.J., Draman, M.S., Conlon, N., Jain, A., Fedarko, N.S., Dasgupta, B. White, K.E. 2006. The role of mutant UDP-N-acetyl-alpha-D-galactosamine- polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 91, 4037 4042.
26. Gattineni, J., Bates, C., Twombley, K., Dwarakanath, V., Robinson, M.L., Goetz, R., Mohammadi, M. Baum, M. 2009. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol 297, F282 F291.
27. Glimcher. 1990. The nature of the mineral component of bone and the mechanism of calcification. In : L. Avioli S. Krane (eds) Metabolic Bone Disease and Clinically Realted Disorders, pp. 125 136. W.B. Saunders Company, Philadelphia.
28. Gutierrez, O.M., Mannstadt, M., Isakova, T., Rauh-Hain, J.A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Juppner, H. Wolf, M. 2008. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359, 584 592.
29. Hyp-Consortium. 1995. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 11, 130 136.
30. Ichikawa, S., Imel, E.A., Kreiter, M.L., Yu, X., Mackenzie, D.S., Sorenson, A.H., Goetz, R., Mohammadi, M., White, K.E. Econs, M.J. 2007. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117, 2684 2691.
31. Imel, E.A. Econs, M.J. 2007. Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23. Pediatr Endocrinol Rev 4 (Suppl. 4 434 439.
32. Jonsson, K.B., Zahradnik, R., Larsson, T., White, K.E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, O. et al. 2003. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348, 1656 1663.
33. Juppner, H. 2007. Novel regulators of phosphate homeostasis and bone metabolism. Ther Apher Dial 11 (Suppl. 1 S3 S22.
34. Karsenty, G. 2006. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 4, 341 348.
35. Kawata, T., Imanishi, Y., Kobayashi, K., Miki, T., Arnold, A., Inaba, M. Nishizawa, Y. 2007. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18, 2683 2688.
36. Krajisnik, T., Bjorklund, P., Marsell, R., Ljunggren, O., Akerstrom, G., Jonsson, K.B., Westin, G. Larsson, T.E. 2007. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195, 125 131.
37. Kumar, R. 2009. Phosphate sensing. Curr Opin Nephrol Hypertens 18, 281 284.
38. Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E. et al. 1997. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390, 45 51.
39. Kurosu, H. Kuro, O.M. 2009. Endocrine fibroblast growth factors as regulators of metabolic homeostasis. Biofactors 35, 52 60.
40. Kurosu, H., Ogawa, Y., Miyoshi, M., Yamamoto, M., Nandi, A., Rosenblatt, K.P., Baum, M.G., Schiavi, S., Hu, M.C., Moe, O.W. Kuro-o, M. 2006. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281, 6120 6123.
41. Larsson, T., Nisbeth, U., Ljunggren, O., Juppner, H. Jonsson, K.B. 2003. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64, 2272 2279.
42. Larsson, T., Marsell, R., Schipani, E., Ohlsson, C., Ljunggren, O., Tenenhouse, H.S., Juppner, H. Jonsson, K.B. 2004. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145, 3087 3094.
43. Larsson, T., Yu, X., Davis, S.I., Draman, M.S., Mooney, S.D., Cullen, M.J. White, K.E. 2005. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90, 2424 2427.
44. Lee, N.K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J.D., Confavreux, C., Dacquin, R., Mee, P.J., McKee, M.D., Jung, D.Y., Zhang, Z., Kim, J.K., Mauvais-Jarvis, F., Ducy, P. Karsenty, G. 2007. Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456 469.
45. Levine, B.S., Kleeman, C.R. Felsenfeld, A.J. 2009. The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport. Clin J Am Soc Nephrol 4, 1866 1877.
46. Liu, B.Y., Guo, J., Lanske, B., Divieti, P., Kronenberg, H.M. Bringhurst, F.R. 1998. Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro. Endocrinology 139, 1952 1964.
47. Liu, S., Tang, W., Zhou, J., Stubbs, J.R., Luo, Q., Pi, M. Quarles, L.D. 2006. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17, 1305 1315.
48. Liu, S., Zhou, J., Tang, W., Menard, R., Feng, J.Q. Quarles, L.D. 2008. Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab 295, E254 E261.
49. Locatelli, F., Cannata-Andia, J.B., Drueke, T.B., Horl, W.H., Fouque, D., Heimburger, O. Ritz, E. 2002. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 17, 723 731.
50. Lorenz-Depiereux, B., Bastepe, M., Benet-Pages, A., Amyere, M., Wagenstaller, J., Muller-Barth, U., Badenhoop, K., Kaiser, S.M., Rittmaster, R.S., Shlossberg, A.H. et al. 2006. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38, 1248 1250.
51. Lorenz-Depiereux, B., Schnabel, D., Tiosano, D., Hausler, G. Strom, T.M. 2010. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86, 267 272.
52. Marsell, R., Grundberg, E., Krajisnik, T., Mallmin, H., Karlsson, M., Mellstrom, D., Orwoll, E., Ohlsson, C., Jonsson, K.B., Ljunggren, O. Larsson, T.E. 2008a. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men. Eur J Endocrinol 158, 125 129.
53. Marsell, R., Krajisnik, T., Goransson, H., Ohlsson, C., Ljunggren, O., Larsson, T.E. Jonsson, K.B. 2008b. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23. Nephrol Dial Transplant 23, 827 833.
54. McCance, R. 1947. Osteomalacia with Looser's nodes(milkman's syndrome) due to a raised resistance to vitamin D aquired about the age of 15 years. Q J Med 16, 33 46.
55. Meyer, R.A. Jr., Meyer, M.H. Gray, R.W. 1989. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 4, 493 500.
56. Mirza, M.A., Hansen, T., Johansson, L., Ahlstrom, H., Larsson, A., Lind, L. Larsson, T.E. 2009a. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant 24, 3125 3131.
57. Mirza, M.A., Larsson, A., Lind, L. Larsson, T.E. 2009b. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205, 385 390.
58. Mitnick, P.D., Goldfarb, S., Slatopolsky, E., Lemann, J. Jr., Gray, R.W. Agus, Z.S. 1980. Calcium and phosphate metabolism in tumoral calcinosis. Ann Intern Med 92, 482 487.
59. Miyauchi, A., Fukase, M., Tsutsumi, M. Fujita, T. 1988. Hemangiopericytoma-induced osteomalacia: tumor transplantation in nude mice causes hypophosphatemia and tumor extracts inhibit renal 25-hydroxyvitamin D 1-hydroxylase activity. J Clin Endocrinol Metab 67, 46 53.
60. Moore, D.D. 2007. Physiology. Sister act. Science 316, 1436 1438.
61. Murer, H., Forster, I., Hernando, N., Lambert, G., Traebert, M. Biber, J. 1999. Posttranscriptional regulation of the proximal tubule NaPi-II transporter in response to PTH and dietary P(i). Am J Physiol 277, F676 F684.
62. Murer, H., Hernando, N., Forster, I. Biber, J. 2000. Proximal tubular phosphate reabsorption: molecular mechanisms. Physiol Rev 80, 1373 1409.
63. Nagai, R., Saito, Y., Ohyama, Y., Aizawa, H., Suga, T., Nakamura, T., Kurabayashi, M. Kuroo, M. 2000. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci 57, 738 746.
64. Ornitz, D.M., Xu, J., Colvin, J.S., McEwen, D.G., MacArthur, C.A., Coulier, F., Gao, G. Goldfarb, M. 1996. Receptor specificity of the fibroblast growth factor family. J Biol Chem 271, 15292 15297.
65. Palmer, P.E. 1966. Tumoural calcinosis. Br J Radiol 39, 518 525.
66. Prie, D., Huart, V., Bakouh, N., Planelles, G., Dellis, O., Gerard, B., Hulin, P., Benque-Blanchet, F., Silve, C., Grandchamp, B. Friedlander, G. 2002. Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 347, 983 991.
67. Razzaque, M.S. 2009. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 5, 611 619.
68. Rhee, Y., Farrow, E., Lee, R., Bivi, N., Lezcano, V., Plotkin, L., White, K.E. T., B. 2009. FGF23 gene expression is upregulated by PTH receptor activation in osteocytes in vitro and in vivo: a parathyroid-bone link influencing the endocrine function of osteocytes. J Bone Miner Res 24 (Suppl. 1 A09001860.
69. Riminucci, M., Collins, M.T., Fedarko, N.S., Cherman, N., Corsi, A., White, K.E., Waguespack, S., Gupta, A., Hannon, T., Econs, M.J., Bianco, P. Gehron Robey, P. 2003. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112, 683 692.
70. Ruchon, A.F., Marcinkiewicz, M., Siegfried, G., Tenenhouse, H.S., DesGroseillers, L., Crine, P. Boileau, G. 1998. Pex mRNA is localized in developing mouse osteoblasts and odontoblasts. J Histochem Cytochem 46, 459 468.
71. Ruchon, A.F., Tenenhouse, H.S., Marcinkiewicz, M., Siegfried, G., Aubin, J.E., DesGroseillers, L., Crine, P. Boileau, G. 2000. Developmental expression and tissue distribution of Phex protein: effect of the Hyp mutation and relationship to bone markers. J Bone Miner Res 15, 1440 1450.
72. Ryan, E.A. Reiss, E. 1984. Oncogenous osteomalacia. Review of the world literature of 42 cases and report of two new cases. Am J Med 77, 501 512.
73. Sabbagh, Y., O'Brien, S.P., Song, W., Boulanger, J.H., Stockmann, A., Arbeeny, C. Schiavi, S.C. 2009. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 20, 2348 2358.
74. Saito, Y., Yamagishi, T., Nakamura, T., Ohyama, Y., Aizawa, H., Suga, T., Matsumura, Y., Masuda, H., Kurabayashi, M., Kuro-o, M., Nabeshima, Y. Nagai, R. 1998. Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 248, 324 329.
75. Scriver, C.R., Reade, T.M., DeLuca, H.F. Hamstra, A.J. 1978. Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med 299, 976 979.
76. Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S. Yamashita, T. 2001. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98, 6500 6505.
77. Shimada, T., Muto, T., Urakawa, I., Yoneya, T., Yamazaki, Y., Okawa, K., Takeuchi, Y., Fujita, T., Fukumoto, S. Yamashita, T. 2002. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143, 3179 3182.
78. Shimada, T., Kakitani, M., Yamazaki, Y., Hasegawa, H., Takeuchi, Y., Fujita, T., Fukumoto, S., Tomizuka, K. Yamashita, T. 2004. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113, 561 568.
79. Shimada, T., Yamazaki, Y., Takahashi, M., Hasegawa, H., Urakawa, I., Oshima, T., Ono, K., Kakitani, M., Tomizuka, K., Fujita, T., Fukumoto, S. Yamashita, T. 2005. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289, F1088 F1095.
80. Silver, J. Naveh-Many, T. 2009. Phosphate and the parathyroid. Kidney Int 75, 898 905.
81. Sitara, D., Razzaque, M.S., Hesse, M., Yoganathan, S., Taguchi, T., Erben, R.G., Juppner, H. Lanske, B. 2004. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23, 421 432.
82. Sitara, D., Razzaque, M.S., St-Arnaud, R., Huang, W., Taguchi, T., Erben, R.G. Lanske, B. 2006. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 169, 2161 2170.
83. St-Arnaud, R. 2008. The direct role of vitamin D on bone homeostasis. Arch Biochem Biophys 473, 225 230.
84. Stubbs, J., Liu, S. Quarles, L.D. 2007. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 20, 302 308.
85. Takeshita, K., Fujimori, T., Kurotaki, Y., Honjo, H., Tsujikawa, H., Yasui, K., Lee, J.K., Kamiya, K., Kitaichi, K., Yamamoto, K. et al. 2004. Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation 109, 1776 1782.
86. Tenenhouse, H.S. 2007. Phosphate transport: molecular basis, regulation and pathophysiology. J Steroid Biochem Mol Biol 103, 572 577.
87. Tenenhouse, H.S., Roy, S., Martel, J. Gauthier, C. 1998. Differential expression, abundance, and regulation of Na+-phosphate cotransporter genes in murine kidney. Am J Physiol 275, F527 F534.
88. Tenenhouse, H.S., Martel, J., Gauthier, C., Segawa, H. Miyamoto, K. 2003. Differential effects of Npt2a gene ablation and X-linked Hyp mutation on renal expression of Npt2c. Am J Physiol Renal Physiol 285, F1271 F1278.
89. Topaz, O., Shurman, D.L., Bergman, R., Indelman, M., Ratajczak, P., Mizrachi, M., Khamaysi, Z., Behar, D., Petronius, D., Friedman, V., Zelikovic, I., Raimer, S., Metzker, A., Richard, G. Sprecher, E. 2004. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36, 579 581.
90. Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S. Yamashita, T. 2006. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770 774.
91. Virkki, L.V., Biber, J., Murer, H. Forster, I.C. 2007. Phosphate transporters: a tale of two solute carrier families. Am J Physiol Renal Physiol 293, F643 F654.
92. Wagner, C.A., Biber, J. Murer, H. 2007. What goes in must come out - the small intestine modulates renal phosphate excretion. Nephrol Dial Transplant 22, 3411 3412.
93. Westerberg, P.A., Linde, T., Wikstrom, B., Ljunggren, O., Stridsberg, M. Larsson, T.E. 2007. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 22, 3202 3207.
94. White, K.E., Carn, G., Lorenz-Depiereux, B., Benet-Pages, A., Strom, T.M. Econs, M.J. 2001a. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60, 2079 2086.
95. White, K.E., Jonsson, K.B., Carn, G., Hampson, G., Spector, T.D., Mannstadt, M., Lorenz-Depiereux, B., Miyauchi, A., Yang, I.M., Ljunggren, O., Meitinger, T., Strom, T.M., Juppner, H. Econs, M.J. 2001b. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86, 497 500.
96. Yamashita, T., Yoshioka, M. Itoh, N. 2000. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277, 494 498.
97. Yamashita, T., Konishi, M., Miyake, A., Inui, K. Itoh, N. 2002. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 277, 28265 28270.
98. Yu, X., Ibrahimi, O.A., Goetz, R., Zhang, F., Davis, S.I., Garringer, H.J., Linhardt, R.J., Ornitz, D.M., Mohammadi, M. White, K.E. 2005. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146, 4647 4656.